Connect with us
Finance Digest is a leading online platform for finance and business news, providing insights on banking, finance, technology, investing,trading, insurance, fintech, and more. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Research Reports


The Artificial Joints Market shall be growing unabatedly in the future. The healthcare vertical is expected to go “personalized” in the next 10 years. Thus, genomics and genetics, along with the other biologic information, going personalized will help in early diagnosis of the disease and also how patients will respond to the treatments. Likewise, the healthcare vertical would be there to make greater strides in the forecast period.

Artificial joints are medical devices that are surgically implanted to conceive for total or fractional replacement of a joint. These are designed to restore normal joint functionality. The artificial joints are called prosthesis. The prosthesis are made up of medical grade metal alloys such as stainless steel, cobalt chrome, titanium, bio-ceramic materials and ultra high molecular weight polyethylene. Hip and knee joints are the most common joint surgeries performing worldwide.

There has been an unprecedented growth in the aging population globally. According to the World Health Organization (WHO), the number of people aged 60 years and over is expected to increase from 605 million to 2 billion over 2000 to 2050. This rise in geriatric population has led to a rise in the incidence and prevalence of chronic arthritis.

Get Sample Copy of this Report@

According to the World Health Organization, in 2010, the global prevalence of rheumatoid arthritis in seven major developed markets (U.S., U.K, France, Japan, Germany, Italy and Spain) was approximately 4.6 million (above the age group of 16). This high prevalence of rheumatoid arthritis presents the artificial joints market with a large patient pool to cater to.

In addition, the U.S. approximately accounts for the largest market share of this market and has reported arthritis as one of the leading cause of disability. According to the Centers for Disease Control and Prevention (CDC), by 2030 an estimated 67 million Americans above the age of 18 years are projected to have doctor diagnosed arthritis.

Thus, rise in aging population coupled with rising incidences of chronic arthritis is expected to push the demand for artificial joints market. Stringent regulatory requirements and lengthy process of FDA approvals have discouraged the medical devices sector in the U.S., which is now eyeing other regions such as Asia and Latin America to launch newer products in the market.

Request for Table of Content@

North America represents the largest regional market for artificial joints in 2012, primarily due to increase in orthopedic procedures, rise in incidence of obesity and introduction of technologically advanced products. American Academy of Orthopedic Surgeons (AAOS), estimated that approximately 2.4 million Americans would be affected by LSS by 2021.

Europe accounts for the second largest market for artificial joints after the U.S. Rising aging population and longer life expectancy has led to a rise in musculoskeletal diseases such as osteoarthritis, rheumatoid arthritis and others in Europe. Asia-Pacific comprises countries such as India, China, Australia, Japan and Malaysia.

Japan and China account for the largest share of the artificial joints market among the Asia-Pacific countries. According to the Government of Japan, it has the fastest growing geriatric population that reached a record of 31.86 million people in September 2013 and the population is expected to reach 95.2 million by 2050.

Access Full Report@

This significant rise in the geriatric population along with technological advancement is expected to boost the artificial joint market in this region. Moreover, emerging economies such as India and China, with a significantly large pool of potential reconstructive surgery patients, represent a big opportunity for the artificial joints market. Rest of the World (RoW) comprises the markets in Latin America, the Middle East and Africa. The market for artificial joints in RoW is primarily fuelled by extensive increase of healthcare infrastructure in Brazil and Mexico.

Major market players operating in the global artificial joints market includes Zimmer Holdings, Inc., Biomet, Inc., DePuy Synthes, Inc., Smith & Nephew plc. Stryker Corporation, Medtronic, Inc., Exactech, Inc., among others.

About Us: Persistence Market Research

Contact Us:

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353

Japan Office: 1-2-1 Kinshi Arca Central Building
14/F Tokyo, 130-0013, Japan
Call 1-888-863-3700

Sales –
Website –

Continue Reading

Why pay for news and opinions when you can get them for free?

       Subscribe for free now!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Posts